MARKET

MESO

MESO

Mesoblast
NASDAQ
13.69
-1.19
-7.97%
Pre Market: 14.43 +0.75 +5.44% 04:01 04/08 EDT
OPEN
13.88
PREV CLOSE
14.87
HIGH
13.99
LOW
13.30
VOLUME
1
TURNOVER
0
52 WEEK HIGH
21.50
52 WEEK LOW
9.61
MARKET CAP
1.76B
P/E (TTM)
-18.5811
1D
5D
1M
3M
1Y
5Y
1D
Mesoblast receives IND clearance from FDA for Ryoncil trial
TipRanks · 1h ago
Reported Earlier, Mesoblast's FDA-Approved Ryoncil Gets IND Clearance For Registrational DMD Trial, To Randomize 76 Patients Aged 5-9 Years Across 7 Infusions Over 9 Months
Benzinga · 4h ago
Mesoblast Wins FDA IND Clearance To Fast-Track Ryoncil Trial In Duchenne Muscular Dystrophy
NASDAQ · 5h ago
Mesoblast wins FDA IND clearance for registrational Ryoncil trial in Duchenne muscular dystrophy
Reuters · 7h ago
MESOBLAST - RECEIVES IND CLEARANCE FROM FDA TO DIRECTLY PROCEED TO REGISTRATIONAL TRIAL FOR APPROVAL OF RYONCIL
Reuters · 8h ago
Mesoblast drops after Ryoncil sales data for March quarter
Seeking Alpha · 19h ago
Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 23h ago
Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket
Benzinga · 1d ago
More
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Webull offers Mesoblast Ltd (ADR) stock information, including NASDAQ: MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.